Skip to main content

Table 1 Patient and treatment characteristics for all patients (left panel) recurrent patients (middle-left panel) and the ARO-analogue subgroup (middle-right panel) and patients with HPV-p16 positive oropharyngeal carcinoma (right panel)

From: Postoperative (chemo) radiation in patients with squamous cell cancers of the head and neck – clinical results from the cohort of the clinical cooperation group “Personalized Radiotherapy in Head and Neck Cancer”

Factors All patients
n = 302
Recurrent
n = 24
ARO-analogue
n = 138
HPVOPC
n = 60
Number Percent Number Percent Number Percent Number Percent
Primary Tumor
 Oropharynx 149 49.3 4 16.7 76 55.1 60 100.0
 Oral cavity 63 20.9 6 25.0 20 14.5 0 0.0
 Hypopharynx 39 12.9 3 12.5 24 17.4 0 0.0
 Larynx 51 16.9 11 45.8 18 13.0 0 0.0
Sex
 male 226 74.8 18 75.0 108 78.3 40 66.7
 female 76 25.2 6 25.0 30 21.7 20 33.3
Age
 < 45 11 3.6 0 0 5 3.6 5 8.3
 45–54 66 21.9 5 20.8 36 26.1 6 10.0
 55–64 114 37.7 7 29.2 63 45.7 24 40.0
 65–74 88 29.1 9 37.5 32 23.2 19 31.7
 > 75 23 7.6 3 12.5 2 1.4 6 10.0
UICC Stage 7th edition (a 8th edition for HPVOPC)
 I 7 2.3 4 16.7 0 0.0 1 (42a) 1.7 (70.0a)
 II 30 9.9 0 0 5 3.6 4 (16a) 6.7 (26.7a)
 III 78 25.8 7 29.2 23 16.7 11 (2a) 18.3 (3.3a)
 IV 187 61.9 13 54.2 110 79.7 44 (0a) 73.3 (0.0a)
Diagnosis class
 First diagnosis 272 90.1 0 0 125 90.6 59 98.3
 Recurrence 24 7.9 24 100.0 11 8.0 1 1.7
 Second primary 6 2.0 0 0 2 1.4 0 0
T-Stage
 T0 2 0.7 2 8.3 2 1.4 0 0.0
 T1 56 18.5 6 25.0 28 20.3 12 20.0
 T2 121 40.1 1 4.2 44 31.9 36 60.0
 T3 74 24.5 6 25.0 40 29.0 10 16.7
 T4 49 16.2 9 37.5 24 17.4 2 3.3
N-Stage
 N0 89 29.5 12 50.0 19 13.8 8 13.3
 N1 58 19.2 6 25.0 23 16.7 9 15
 N2a 23 7.6 0 0 15 10.9 10 16.7
 N2b 85 28.1 5 20.8 47 34.1 25 41.7
 N2c 42 13.9 1 4.2 30 21.7 8 13.3
 N3 5 1.7 0 0 4 2.9 0 0
M-Stage
 M0 302 100 24 100 138 100 60 100
 M1 0 0 0 0 0 0 0 0
Resection status (R-Status)
 R0 150 51.0 7 33.3 47 35.1 26 44.1
 R0-Close margin 75 25.5 7 33.3 43 32.1 12 20.3
 R1 69 23.5 7 33.3 44 32.8 21 35.6
 N/A 8   3   4   1  
Extracapsular extension (ECE)
 no (N0) 89 29.8 12 52.5 19 13.9 8 13.3
 no (N+) 132 44.1 6 26.1 59 43.1 34 56.7
 yes 78 26.1 5 21.7 59 43.1 18 30.0
 N/A 3   1   1   0  
Perineural invasion (PNI)
 no (Pn0) 198 83.5 8 88.9 86 82.7 41 87.2
 yes (Pn1) 39 16.5 1 11.1 18 17.3 6 12.8
 N/A 65   15   34   13  
Lymphatic Invasion (LI)
 no (L0) 201 73.4 11 78.6 82 66.1 40 69.0
 yes (L1) 73 26.6 3 21.4 42 33.9 18 31.0
 N/A 28   10   14   2  
Vascular Invasion (VI)
 no (V0) 266 97.1 12 100 119 96.0 55 96.5
 yes (V1) 8 2.9 0 0 5 4.0 2 3.5
 N/A 28   12   14   3  
Grading
 G1 9 3.0 2 8.7 2 1.5 0 0.0
 G2 119 39.5 11 47.8 45 32.8 11 18.3
 G3 173 57.5 10 43.4 90 65.7 49 81.7
 N/A 1   1   1   0  
HPV p16
 negative 159 68.2 11 73.3 66 61.7 0 0.0
 positive 74 31.8 4 26.7 41 38.8 60 100.0
 HPVOPC 60 20.5 1 6.7 36 25.2 60 100.0
 N/A 69   9   31   0  
RT dose in tumor bed
 < 60 Gy (not completed) 9 3 2 8.3 4 2.9 2 3.3
 60–63.9 Gy 8 2.6 0 0 6 4.3 3 5.0
 64 Gy 263 87.1 21 87.5 120 87 52 86.7
 66 Gy 22 7.3 1 4.2 8 4.8 3 5.0
RT technique
 3d-conformal 245 81.1 21 87.5 116 84.1 41 68.3
 IMRT 57 18.9 3 12.5 22 15.9 19 31.7
Concomitant chemotherapy
 no Chx 126 41.7 10 41.7 0 0.0 16 26.7
  despite indicated 43 14.2 5 20.8 0 0.0 4 6.7
   Med. 20   4   0 0.0 2 3.3
   Pat. Refusal 23   1   0 0.0 2 3.3
  Any Chemo 176 58.3 14 58.3 138 100.0 44 73.3
   CDDP/5-FU 138 78.4 11 45.8 138 100.0 36 81.8
   CDDP mono 9 5.1 1 4.2 0 0.0 3 6.8
   Cetuximab 1 0.6 0 0 0 0.0 0 0.0
   5-FU/MMC 8 4.5 1 4.2 0 0.0 3 6.8
   MMC 20 11.4 1 4.2 0 0.0 2 4.5
  Chemo completed 147 83.5 14 58.3 120 87.0 36 81.8
  Chemo stopped 29 16.5 0   18 13.0 8 18.1
   patient refused 8   0   6   2  
  Worsening condition 7   0   3   3  
   cytopenia 9   0   4   1  
   reaction to chemo 5   0   5   2  
Death causes
 Tumor-related 42   3   21   1  
 comorbidities 40   3   13   6  
 therapy-associated 2   0   0   1  
 Second primary 8   0   4   0  
 other 5   0   3   0  
  1. aThe UICC 8th edition stage is shown in parenthesis (HPVOPC only)